Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would ...

FDA approved Ryoncil ® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), ...

Patients with ankylosing spondylitis and IBD exhibit distinct clinical and radiographic features, compared against those without comorbid IBD.

AbbVie Inc . (NYSE:ABBV) delivered strong financial results for Q4 2024, surpassing analysts' expectations with an earnings per share (EPS) of $2.16, compared to the forecast of $2.06. The company ...

The Annals of Pharmacotherapy. 2008;42(6):790-805.

Patients with rheumatoid arthritis are at increased risk for infection related to disease activity, comorbidities and immunomodulatory therapy. Biological therapies are associated with a greater risk ...